Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 19/20 | 0.48 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20901306 | 0.90 | CHRM1 (0.48) | CHRM1CHRM5CHRM4CHRM2 | |
| SCHEMBL20901308 | 0.80 | CHRM1 (0.47) | CHRM1CHRM5CHRM4CHRM2 | |
| SCHEMBL15618700 | 0.80 | CHRM1 (0.53) | CHRM1CHRM5CHRM4CHRM2TP53 | |
| SCHEMBL3003076 | 0.79 | CHRM1 (0.52) | CHRM1CHRM5CHRM4CHRM2 | |
| SCHEMBL2998936 | 0.78 | CHRM1 (0.51) | CHRM1CHRM5CHRM4CHRM2 | |
| SCHEMBL15618889 | 0.77 | MAPT (0.52) | CHRM1CHRM5CHRM2 | |
| SCHEMBL15618674 | 0.74 | CHRM1 (0.46) | CHRM1CHRM5CHRM4CHRM2TP53 | |
| SCHEMBL12128829 | 0.74 | CHRM1 (0.46) | CHRM1CHRM5CHRM4CHRM2 | |
| SCHEMBL2996155 | 0.74 | CHRM1 (0.50) | CHRM1CHRM5CHRM4CHRM2 | |
| SCHEMBL13209533 | 0.73 | CHRM1 (0.45) | CHRM1CHRM5CHRM4CHRM2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10259802-B2 | Bicyclic aza compounds as muscarinic M1 receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10259802-B2 | Bicyclic aza compounds as muscarinic M1 receptor antagonists | CHRM1, CHRM2, CHRM5 | CHRM1 1/4885CHRM5 3/4885CHRM4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.